RenovoRx Case Study Shows Potential for Targeted Pancreatic Cancer Therapy

Event summary

  • RenovoRx published a peer-reviewed case study in Radiology Case Reports demonstrating the potential of its TAMP™ therapy for locally advanced pancreatic cancer (LAPC).
  • The study, conducted by Moffitt Cancer Center, showed a 52% reduction in tumor metabolic activity using PET-CT imaging after intra-arterial gemcitabine delivery via RenovoCath®.
  • The procedure involved embolizing a pancreaticoduodenal artery side branch with coils and surgical glue to optimize drug delivery.
  • RenovoRx reported $1.1 million in RenovoCath sales for 2025 and $563,000 in Q1 2026, with plans to expand commercialization.

The big picture

RenovoRx's case study highlights the potential of targeted intra-arterial therapy for pancreatic cancer, a challenging and underserved indication. The company's TAMP™ platform aims to improve drug delivery precision, reducing systemic toxicity and enhancing efficacy. As RenovoRx scales commercialization, its ability to demonstrate consistent clinical outcomes will be critical for broader adoption and regulatory approval.

What we're watching

Clinical Validation
Whether the case study results can be replicated in larger trials, particularly the Phase III TIGeR-PaC trial.
Commercial Expansion
The pace at which RenovoRx can expand RenovoCath adoption in high-volume cancer centers.
Regulatory Pathway
How the FDA will evaluate the combination of RenovoCath with gemcitabine under the investigational new drug application.

Related topics

Biotechnology